CRISPR Enables In Vivo CAR T Cell Production
In vivo gene editing strategy generates CAR T cells directly inside the body – sidestepping costly manufacturing
-
1
A new CRISPR-based method enables in vivo production of CAR T cells, addressing manufacturing bottlenecks in cell therapy.
-
2
The approach uses a two-vector system that inserts therapeutic genes into a T cell-specific genomic site.
-
3
In humanized mouse models, the system generated CAR T cells that reached therapeutic levels and induced B cell depletion.
-
4
Engineered delivery components enhance specificity and efficiency, targeting T cells and improving uptake.
-
5
If successful in humans, this method could reduce costs and increase access to CAR T therapies by eliminating ex vivo processes.
